Both psoriasis and atopic dermatitis (AD) are not only associated with an impaired stratum corneum barrier, but also with abnormal expression of the tight junction (TJ) proteins. Because host defense peptides, including LL-37, are overexpressed in lesional psoriatic skin but are downregulated in lesional AD skin, we hypothesized that LL-37 might regulate the TJ function in keratinocytes. We demonstrated that LL-37 selectively increased the expression of several claudins and occludin, and enhanced their membrane distribution. Furthermore, LL-37 elevated the transepithelial electrical resistance while reducing the paracellular permeability of keratinocyte layers, and this activity was weakened by the claudin inhibitor ochratoxin A. A characterization of the molecular mechanism underlying the regulation of the TJ barrier by LL-37 revealed that LL-37 induced the activation of the Rac1, atypical PKC, glycogen synthase kinase-3 and PI3K pathways, and the specific inhibition of these pathways reversed the LL-37-mediated regulation of TJ function. In addition, LL-37 enhanced the expression of differentiation markers under the control of ochratoxin A, suggesting an association between LL-37-induced TJ function and keratinocyte differentiation. These data provide novel evidence that, in addition to its antimicrobial and other immunoregulatory functions, LL-37 contributes to cutaneous immunity by strengthening the skin's barrier function.

Keywords:
Antimicrobial peptide, Cathelicidin LL-37, Keratinocyte, Skin barrier, Tight junction
1.
Niyonsaba F, Nagaoka I, Ogawa H, Okumura K: Multifunctional antimicrobial proteins and peptides: natural activators of immune systems. Curr Pharm Des 2009;15:2393-2413.
2.
Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995;374:1-5.
3.
Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zugel U, Bikle DD, Modlin RL, Gallo RL: Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007;117:803-811.
4.
Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454-457.
5.
Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
6.
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
7.
Harder J, Dressel S, Wittersheim M, Cordes J, Meyer-Hoffert U, Mrowietz U, Folster-Holst R, Proksch E, Schroder JM, Schwarz T, Glaser R: Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol 2010;130:1355-1364.
8.
De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA: Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011;127:773-786.e7.
9.
Kirschner N, Rosenthal R, Furuse M, Moll I, Fromm M, Brandner JM: Contribution of tight junction proteins to ion, macromolecule, and water barrier in keratinocytes. J Invest Dermatol 2013;133:1161-1169.
10.
Matter K, Aijaz S, Tsapara A, Balda MS: Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. Curr Opin Cell Biol 2005;17:453-458.
11.
Niessen CM: Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007;127:2525-2532.
12.
Anderson JM, Van Itallie CM: Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009;1:a002584.
13.
Van Itallie CM, Anderson JM: Claudins and epithelial paracellular transport. Annu Rev Physiol 2006;68:403-429.
14.
Itoh K, Kawasaki S, Kawamoto S, Seishima M, Chiba H, Michibata H, Wakimoto K, Imai Y, Minesaki Y, Otsuji M, Okubo K: Identification of differentially expressed genes in psoriasis using expression profiling approaches. Exp Dermatol 2005;14:667-674.
15.
Peltonen S, Riehokainen J, Pummi K, Peltonen J: Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis. Br J Dermatol 2007;156:466-472.
16.
Kirschner N, Poetzl C, von den Driesch P, Wladykowski E, Moll I, Behne MJ, Brandner JM: Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am J Pathol 2009;175:1095-1106.
17.
Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H: Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007;127:594-604.
18.
Yuki T, Haratake A, Koishikawa H, Morita K, Miyachi Y, Inoue S: Tight junction proteins in keratinocytes: localization and contribution to barrier function. Exp Dermatol 2007;16:324-330.
19.
Gonzalez-Mariscal L, Tapia R, Chamorro D: Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 2008;1778:729-756.
20.
Baumer Y, Spindler V, Werthmann RC, Bunemann M, Waschke J: Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. J Cell Physiol 2009;220:716-726.
21.
Doble BW, Woodgett JR: Gsk-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-1186.
22.
Severson EA, Kwon M, Hilgarth RS, Parkos CA, Nusrat A: Glycogen synthase kinase 3 (GSK-3) influences epithelial barrier function by regulating occludin, claudin-1 and E-cadherin expression. Biochem Biophys Res Commun 2010;397:592-597.
23.
Kirschner N, Rosenthal R, Gunzel D, Moll I, Brandner JM: Tight junctions and differentiation - a chicken or the egg question? Exp Dermatol 2012;21:171-175.
24.
Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S: Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156:1099-1111.
25.
Kirschner N, Houdek P, Fromm M, Moll I, Brandner JM: Tight junctions form a barrier in human epidermis. Eur J Cell Biol 2010;89:839-842.
26.
Milatz S, Krug SM, Rosenthal R, Gunzel D, Muller D, Schulzke JD, Amasheh S, Fromm M: Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. Biochim Biophys Acta 2010;1798:2048-2057.
27.
Van Itallie CM, Fanning AS, Anderson JM: Reversal of charge selectivity in cation or anion-selective epithelial lines by expression of different claudins. Am J Physiol Renal Physiol 2003;285:F1078-F1084.
28.
Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K: Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 1996;134:1031-1049.
29.
Van Itallie CM, Fanning AS, Bridges A, Anderson JM: Zo-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol Biol Cell 2009;20:3930-3940.
30.
Van Itallie CM, Fanning AS, Holmes J, Anderson JM: Occludin is required for cytokine-induced regulation of tight junction barriers. J Cell Sci 2010;123:2844-2852.
31.
Fanning AS, Van Itallie CM, Anderson JM: Zonula occludens-1 and -2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia. Mol Biol Cell 2012;23:577-590.
32.
Liu KC, Jacobs DT, Dunn BD, Fanning AS, Cheney RE: Myosin-X functions in polarized epithelial cells. Mol Biol Cell 2012;23:1675-1687.
33.
Kirschner N, Haftek M, Niessen CM, Behne MJ, Furuse M, Moll I, Brandner JM: CD44 regulates tight-junction assembly and barrier function. J Invest Dermatol 2011;131:932-943.
34.
Turksen K, Troy TC: Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development 2002;129:1775-1784.
35.
Helfrich I, Schmitz A, Zigrino P, Michels C, Haase I, le Bivic A, Leitges M, Niessen CM: Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol 2007;127:782-791.
36.
Nunbhakdi-Craig V, Machleidt T, Ogris E, Bellotto D, White CL 3rd, Sontag E: Protein phosphatase 2a associates with and regulates atypical PKC and the epithelial tight junction complex. J Cell Biol 2002;158:967-978.
37.
Stuart RO, Nigam SK: Regulated assembly of tight junctions by protein kinase C. Proc Natl Acad Sci USA 1995;92:6072-6076.
38.
Mertens AE, Rygiel TP, Olivo C, van der Kammen R, Collard JG: The RAC activator Tiam1 controls tight junction biogenesis in keratinocytes through binding to and activation of the par polarity complex. J Cell Biol 2005;170:1029-1037.
39.
Yuki T, Hachiya A, Kusaka A, Sriwiriyanont P, Visscher MO, Morita K, Muto M, Miyachi Y, Sugiyama Y, Inoue S: Characterization of tight junctions and their disruption by UVB in human epidermis and cultured keratinocytes. J Invest Dermatol 2011;131:744-752.
40.
Nijhara R, van Hennik PB, Gignac ML, Kruhlak MJ, Hordijk PL, Delon J, Shaw S: Rac1 mediates collapse of microvilli on chemokine-activated T lymphocytes. J Immunol 2004;173:4985-4993.
41.
Weston C, Gordon C, Teressa G, Hod E, Ren XD, Prives J: Cooperative regulation by Rac and Rho of agrin-induced acetylcholine receptor clustering in muscle cells. J Biol Chem 2003;278:6450-6455.
42.
Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA, Shimokawa H, Kaibuchi K, Ikezu T: Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 2006;107:4770-4780.
43.
Bokoch GM, Vlahos CJ, Wang Y, Knaus UG, Traynor-Kaplan AE: Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Biochem J 1996;315(pt 3):775-779.
44.
Little D, Dean RA, Young KM, McKane SA, Martin LD, Jones SL, Blikslager AT: PI3K signaling is required for prostaglandin-induced mucosal recovery in ischemia-injured porcine ileum. Am J Physiol Gastrointest Liver Physiol 2003;284:G46-G56.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.